CN204766639U - Magnetic conductive microsphere for medical use - Google Patents
Magnetic conductive microsphere for medical use Download PDFInfo
- Publication number
- CN204766639U CN204766639U CN201520383009.5U CN201520383009U CN204766639U CN 204766639 U CN204766639 U CN 204766639U CN 201520383009 U CN201520383009 U CN 201520383009U CN 204766639 U CN204766639 U CN 204766639U
- Authority
- CN
- China
- Prior art keywords
- microsphere
- magnetic conductance
- magnetic
- conductance
- substrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000005291 magnetic effect Effects 0.000 title claims abstract description 250
- 239000004005 microsphere Substances 0.000 title claims abstract description 197
- 239000006247 magnetic powder Substances 0.000 claims abstract description 38
- 239000013543 active substance Substances 0.000 claims abstract description 24
- 239000000463 material Substances 0.000 claims description 35
- 239000000758 substrate Substances 0.000 claims description 33
- 239000000126 substance Substances 0.000 claims description 25
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 21
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 19
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 19
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 19
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 18
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 18
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 18
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 239000000835 fiber Substances 0.000 claims description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 10
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 229910052712 strontium Inorganic materials 0.000 claims description 7
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 6
- 230000000975 bioactive effect Effects 0.000 claims description 6
- 235000009508 confectionery Nutrition 0.000 claims description 6
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 229910045601 alloy Inorganic materials 0.000 claims description 3
- 239000000956 alloy Substances 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000010941 cobalt Substances 0.000 claims description 3
- 229910017052 cobalt Inorganic materials 0.000 claims description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 3
- 239000003302 ferromagnetic material Substances 0.000 claims description 3
- 229920002521 macromolecule Polymers 0.000 claims description 3
- 150000002772 monosaccharides Chemical class 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- 239000002907 paramagnetic material Substances 0.000 claims description 3
- 229910052701 rubidium Inorganic materials 0.000 claims description 3
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims description 3
- -1 sugar alcohols compound Chemical class 0.000 claims description 3
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 239000011148 porous material Substances 0.000 abstract description 9
- 239000011159 matrix material Substances 0.000 abstract description 8
- 239000011257 shell material Substances 0.000 description 28
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000002245 particle Substances 0.000 description 16
- 230000005415 magnetization Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 235000010323 ascorbic acid Nutrition 0.000 description 12
- 229960005070 ascorbic acid Drugs 0.000 description 12
- 239000011668 ascorbic acid Substances 0.000 description 12
- 238000001125 extrusion Methods 0.000 description 12
- 238000005563 spheronization Methods 0.000 description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 9
- 239000002994 raw material Substances 0.000 description 7
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000000465 moulding Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000008240 homogeneous mixture Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 229960000448 lactic acid Drugs 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910000859 α-Fe Inorganic materials 0.000 description 4
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 2
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 2
- 229910000521 B alloy Inorganic materials 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- ICTWBZWATZZWDC-UHFFFAOYSA-N [B].[Rb] Chemical compound [B].[Rb] ICTWBZWATZZWDC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000009740 moulding (composite fabrication) Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Abstract
The utility model discloses a magnetic conductance microballon for medical treatment, which comprises a porous matrix and magnetic powder dispersed in the matrix. In addition, active substances may also be added, also dispersed in the matrix. The porous matrix allows the magnetically permeable microspheres to carry active substances or to adsorb specific targets. Since the magnetically conductive microspheres comprise a porous matrix, active substances with different sizes and different characteristics can be selectively adsorbed by controlling the pore size of the porous matrix. In addition, the magnetic conductive microsphere can pass through an additional coated shell layer so as to increase the stability and more different release characteristics of the magnetic conductive microsphere.
Description
Technical field
This utility model relates to a kind of pharmaceutical carrier, and in particular to a kind of magnetic conductance pharmaceutical carrier.
Background technology
The magnetic conductance carrier (magneticcarrier) developed in biotechnology at present only has and is applied on the testing reagent of laboratory among a small circle, its Related product is commonly referred to magnetic bead (magneticbead), and it is obtained by chemical modification by single magnetic powder mostly.Such as, engage with medicine after can modifying the surface of other single magnetic powder with antibody again and form so-called immunomagnetic beads, or direct drug injection thing parcel other single magnetic powder forms, its particle diameter is generally about 20 ~ 50 μm.In some example, also available polymeric PTC materials magnetic powder, or the surface being sprayed on core after allowing magnetic powder be scattered in low concentration macromolecular solution again becomes the mode of core coating, and form magnetic bead, its particle diameter is generally between 30 ~ 100 μm.
Because above-mentioned various magnetic bead price is mostly too expensive, so (such as muscle, subcutaneous or intravenous injection, or peroral dosage form) is quite rare in clinical practice.Therefore, need a kind of magnetic conductance carrier of novelty at present badly, to solve existing magnetic conductance carrier institute problems faced.
Utility model content
The purpose of this utility model is, provides a kind of therapeutic medical magnetic conductance microsphere, thus overcomes above-mentioned problems of the prior art.
Therefore, one side of the present utility model is, provide a kind of therapeutic medical magnetic conductance microsphere, it comprises the first substrate and multiple magnetic powder, and it intersperses among in the first substrate.Wherein the first substrate has multiple hole, and the material of the first substrate is upgraded fiber element or starch.And the material of multiple magnetic powder is ferromagnetic material or paramagnetic material, to make multiple magnetic powder, there is magnetic and maybe can be induced magnetic.
According to this utility model one embodiment, the aperture of above-mentioned hole is 0.1 ~ 20 μm.
According to another embodiment of this utility model, above-mentioned upgraded fiber element is hydroxypropyl methylcellulose (hydroxypropylmethylcellulose; HPMC), hydroxypropyl cellulose (hydroxypropylcellulose; HPC), hydroxyethyl-cellulose (hydroxyethylcellulose; HEC), microcrystalline Cellulose (microcrystallinecellulose, MCC) or its combination in any.
According to another embodiment of this utility model, the material of above-mentioned magnetic powder is the element state of ferrum, cobalt, nickel, rubidium or strontium, oxide, alloy, salt or its combination in any.
According to another embodiment of this utility model, above-mentioned magnetic conductance microsphere also comprises the first active substance, and it intersperses among in the first substrate or multiple hole, and the first active substance is for having bioactive chemical substance or biological substance.
According to another embodiment of this utility model, above-mentioned magnetic conductance microsphere also comprises shell, and it is coated on the surface of the first substrate.
According to this utility model another embodiment, the material of above-mentioned shell is single candy, two candy, sugar alcohol, macromolecule or have fatty acid or its esters of 5 ~ 50 carbon.
Another aspect of the present utility model is, provides a kind of therapeutic medical magnetic conductance complex microsphere, and it comprises the second substrate and multiple any one above-mentioned magnetic conductance microsphere.
According to this utility model one embodiment, the material of the second above-mentioned substrate is micromolecular water-soluble substances, and water-soluble substances is monosaccharide, aminoacid, organic acid or sugar alcohols compound.
According to another embodiment of this utility model, above-mentioned magnetic conductance complex microsphere also comprises the second active substance, and it intersperses among in the second substrate, and described second active substance is for having bioactive chemical substance or biological substance.
The beneficial effect of magnetic conductance microsphere of the present utility model is, magnetic conductance microsphere comprises porous matrix, therefore optionally adsorbs vary in size and active substance that characteristic is different by controlling the pore size of porous matrix.Magnetic conductance microsphere also by shell coated in addition, to increase the stability of magnetic conductance microsphere and more different release characteristics.
Above-mentioned utility model content aims to provide the simplification summary of present disclosure, possesses basic understanding to make reader to present disclosure.This utility model content is not the complete overview of present disclosure, and its purpose is not being pointed out the key/critical element of this utility model embodiment or defining scope of the present utility model.After consulting following description, have in this utility model art and usually know that the knowledgeable is when can understand essence spirit of the present utility model and other utility model objects easily, and the technological means that adopts of this utility model and enforcement aspect.
Accompanying drawing explanation
For following and other objects, feature, advantage and embodiment of the present utility model can be become apparent, appended the description of the drawings is as follows:
Fig. 1 is the structural profile schematic diagram of a kind of magnetic conductance microsphere according to an embodiment of the present utility model;
Fig. 2 is a kind of structural profile schematic diagram with the magnetic conductance microsphere of shell according to another embodiment of the present utility model; And
Fig. 3 is the structural profile schematic diagram of a kind of magnetic conductance complex microsphere according to another embodiment of the present utility model.
Detailed description of the invention
According to above-mentioned, provide a kind of therapeutic medical magnetic conductance microsphere and preparation method thereof.Below describe in, the exemplary construction of above-mentioned magnetic conductance microsphere and preparation method thereof and the preparation method of its example will be introduced.In order to make describing of present disclosure more detailed and complete, hereafter propose illustrative description for enforcement aspect of the present utility model and specific embodiment; But this not implements or uses the unique forms of this utility model specific embodiment.Cover in embodiment multiple specific embodiment feature and in order to construction and these specific embodiments of operation method step with its sequentially.But, other specific embodiments also can be utilized to reach identical or impartial function and sequence of steps.
The structure of magnetic conductance microsphere
Please refer to Fig. 1, Fig. 1 is the structural profile schematic diagram of a kind of magnetic conductance microsphere (magneticpellet) according to an embodiment of the present utility model.In FIG, as the magnetic powder 112 that the magnetic conductance microsphere 100 of carrier comprises the first substrate 110 and intersperses among in the first substrate 110.
Above-mentioned first substrate 110 is solid or loose structure, and its content is about 2.5 ~ 50 weight portions, such as, can be 2.5,3,5,7,10,15,20,25,30,35,40,45 or 50 weight portions.The material of the first substrate 110 is upgraded fiber element or starch.Above-mentioned upgraded fiber element such as can be hydroxypropyl methylcellulose (hydroxypropylmethylcellulose; HPMC), hydroxypropyl cellulose (hydroxypropylcellulose; HPC), hydroxyethyl-cellulose (hydroxyethylcellulose; HEC), microcrystalline Cellulose (microcrystallinecellulose, MCC) or its combination in any.Such as, at 25 DEG C, by the hydroxypropyl methylcellulose aqueous solution of the higher 2 ~ 10wt% of viscosity as binding agent, the material that other water miscible upgraded fibers elements mix excipient can be added.
The content of above-mentioned magnetic powder 112 is about 5 ~ 25 weight portions, such as, can be 5,7,10,15,20 or 25 weight portions.The material of magnetic powder 112 itself has magnetic maybe can be induced out magnetic, therefore can comprise any available paramagnetic or ferromagnetic material.For example, it can be the element state of available ferrum, cobalt, nickel, rubidium or strontium, oxide, alloy, salt or its combination in any.
According to an embodiment, above-mentioned magnetic conductance microsphere 100 also can comprise the first active substance 114 be scattered among the first substrate 110, the content of the first active substance 114 is 30 ~ 70 weight portions, such as, can be 30,35,40,45,50,55,60,65 or 70 weight portions.The material of the first active substance 114 comprises synthetic or has bioactive chemical substance (as nutriment or medicine) or biological substance (as ferment, born of the same parents' device or cell) from any available of natural goods extraction.
Please refer to Fig. 2, Fig. 2 is a kind of structural profile schematic diagram with the magnetic conductance microsphere of shell according to another embodiment of the present utility model.In fig. 2, magnetic conductance microsphere 200 comprises the magnetic conductance microsphere 100 of Fig. 1 and the shell 210 of coated magnetic conductance microsphere 100.Wherein the structure of magnetic conductance microsphere 100 is described above, does not repeat them here.
On pharmacopedics, above-mentioned shell 210 can be sugar-coat or film clothing, can be used to as magnetic conductance microsphere provides new function, such as, provide buffer action, Co ntrolled release effect or control adsorption etc.With sugar-coat, its function, except improving the sense of taste, also can increase stability and the hardness of magnetic conductance microsphere 100.With film clothing, its type such as can be divided into time controlled release type, pH dependent form, moistureproof wet type, elastic force Anti-pressure, long-acting type and large intestine release type.Therefore, after having added shell 210, except can increasing the stability of magnetic conductance microsphere 100, shell 210 disintegrate under selected environment can also be controlled, allow magnetic conductance microsphere 100 contact external environment, discharge active substance.
When shell 210 is sugar-coat, its material such as can be single candy, two candy or sugar alcohol.When shell 210 is film clothing, its material such as can be macromolecule, or has fatty acid or its esters of 5 ~ 50 carbon.In addition, the material of shell 210 also can comprise arbitrary first active substance as above.
Please refer to Fig. 3, Fig. 3 is the structural profile schematic diagram of a kind of magnetic conductance complex microsphere according to another embodiment of the present utility model.In figure 3, magnetic conductance complex microsphere 300 forms for allowing the magnetic conductance microsphere 200 (Fig. 2) of multiple magnetic conductance microsphere 100 (Fig. 1) without shell and band shell be scattered among the second substrate 310.But be not limited thereto, also can only select magnetic conductance microsphere 100 or magnetic conductance microsphere 200 to prepare magnetic conductance complex microsphere 300.
Magnetic conductance microsphere 100,200 or the two combination is allowed to be scattered in the second substrate 310, form magnetic conductance complex microsphere 300, not only can increase the stability of magnetic conductance microsphere 100 or 200, the object of active substance in releasing by parts magnetic conductance microsphere 100 or 200 can also be reached.Therefore, the material of the second substrate 310 is generally micromolecular water-soluble substances, such as monosaccharide, aminoacid, organic acid or sugar alcohols compound.
In addition, the second suitable active substance 314 can also be selected, allow it also be dispersed in the second substrate 310.Material as the first active substance 114, second active substance 314 also can comprise synthetic or have bioactive chemical substance (as nutriment or medicine) or biological substance (as ferment, born of the same parents' device or cell) from any available of natural goods extraction.
According to an embodiment of the present utility model, the particle diameter of above-mentioned various magnetic conductance microsphere is about 20 ~ 3,000 micron.For example, when the particle diameter of magnetic conductance microsphere is 20 ~ 70 microns, magnetic conductance microsphere can enter blood circulation or soma's interstitial and tract by intravenous injection or other injection systems in organism.It can thus be appreciated that magnetic conductance microsphere provided by the utility model can rest in blood circulation, with the object reaching treatment or detect.
When the particle diameter of magnetic conductance microsphere is 40 ~ 200 microns, magnetic conductance microsphere can be applicable to muscle, subcutaneous or lumbar injection, to be stranded in raw soma or organ.It can thus be appreciated that magnetic conductance microsphere provided by the utility model can rest in muscle, subcutaneous or Intraabdominal arbitrary organ, with the object reaching treatment or detect.
When the particle diameter of magnetic conductance microsphere is 150 ~ 3,000 micron, magnetic conductance microsphere can enter digestive tract, enters from oral cavity, via throat, esophagus, Stomach duodenum, jejunum, ileum and large intestine, then is discharged by anus.It can thus be appreciated that magnetic conductance microsphere provided by the utility model can rest in gastral arbitrary organ, with the object reaching treatment or detect.When magnetic conductance microsphere excretes, because of structure maintenance and the magnetic of magnetic conductance microsphere, by magnetic apparatus, magnetic conductance microsphere and other Excretas are separated.
The preparation method of magnetic conductance microsphere
When the material of the first substrate is upgraded fiber element, first by the hydroxypropyl methylcellulose (HPMC of 5wt%, its viscosity is higher) aqueous solution is added in the homogeneous mixture of microcrystalline Cellulose (MCC), magnetic powder and active substance, again by its Homogeneous phase mixing, obtain the mixture of microspheres of non-molding.
Next, the step of extrusion spheronization (allow microsphere molding) is carried out.In the step of extrusion spheronization, adjustable extrudes the aperture of orifice plate and centrifugal round as a ball required rotating speed, obtains the magnetic conductance microsphere of different-grain diameter.
After the step of extrusion spheronization, then the step will carried out below how much deciding according to the addition of upgraded fiber element above.When the content of upgraded fiber element is more, carry out the step of fluidized drying, after removing unnecessary moisture, solid magnetic conductance microsphere can be obtained.
When the content of upgraded fiber element is less, after the step of extrusion spheronization, then remove moisture instead by the mode of drying in the shade, porous magnetic conductance microsphere can be obtained.If in the mixture of microspheres of aforementioned non-molding, have when adding water-soluble substances again, then the magnetic conductance microsphere after drying in the shade can be allowed to be dipped in water a period of time again.Then, allow water-soluble substances be dissolved in the water, then be heated oven dry, the porous magnetic conductance microsphere that hole number is more and aperture is larger can be obtained.By the porous magnetic conductance microsphere additionally added prepared by water-soluble substances method, after its water-soluble substances is dissolved in the water, through the measurement of aperture tester, its aperture can be recorded up to 0.1 ~ 20 μm.
If test the structural strength (being inversely proportional to total pore volume of microsphere) of microsphere with pressure, that is see pressure is increased to how many times, magnetic conductance microsphere just can be crushed.Acquired results is, the pressure that above-mentioned solid magnetic conductance microsphere can bear is approximately 100 ~ 400mPa.And there is multiple hole due to above-mentioned porous magnetic conductance microsphere, its pressure that can bear then is about 20 ~ 100mPa.
When the material of the first substrate be water-fast long-chain fatty acid or its esters time, the preparation method of magnetic conductance microsphere is as follows.First long-chain fatty acid or its esters are heated to molten condition, are then added in the homogeneous mixture of magnetic powder and active substance, and by its Homogeneous phase mixing.After its cooling, sequentially carry out pulverizing and sifting step, obtain the magnetic conductance microsphere of required size size.
The Magnetic Measurement of magnetic conductance microsphere
In the following embodiments, the strip magnetic measurement method of magnetic conductance microsphere is as follows.Magnetic conductance microsphere 6 before first getting magnetization or after magnetization, uses hand-held probe type Gauss instrument to measure its magnetic, then divided by 6, averages.Because magnetic force is action at distance power, and magnetic pole (having south poles) is directive, so the magnetic recorded can change to some extent along with the difference of monitoring Azimuth & Range.Therefore magnetic measured value, all gets the maximum recorded.The unit of magnetic is Gauss's (Gauss writes a Chinese character in simplified form into G).
Embodiment one: solid magnetic conductance microsphere
Experimental example 1-1 to 1-8 has the structure of the solid magnetic conductance microsphere 100 shown in Fig. 1 below.The magnetic conductance microsphere that experimental example 1-1 to 1-8 provides is made for utilizing extrusion spheronization method.In detail, the magnetic powder in the magnetic conductance microsphere that provides of experimental example 1-1 to 1-8 is for using strontium ferrite (SrO6Fe
2o
3, can be used to prepare permanent magnet, purchased from magnesium Lige Co., Ltd), form prepared by microcrystalline Cellulose (purchased from Ming Tai company) and hydroxypropyl methylcellulose (purchased from Ming Tai company).The preparation method of experimental example 1-1 to 1-8 is as described below.
First prepare hydroxypropyl methylcellulose (HPMC) aqueous solution of 5wt%, then added among the magnetic powder of strontium ferrite and the homogeneous mixture of microcrystalline Cellulose (MCC), allow Homogeneous phase mixing each other.Subsequently, use extrusion spheronization machine (Ying Ge company, model E50), by the required rotating speed of extrusion cavities panel aperture and adjustment, obtain the magnetic conductance microsphere of different-grain diameter.Such as add that 300 ~ 800rpm rotating speed is to carry out centrifugal round as a ball step, can obtain the magnetic conductance microsphere that particle diameter is 0.8 ~ 2.0mm with the orifice plate of extruding in 1.0 ~ 2.0mm aperture.If add that 800 ~ Isosorbide-5-Nitrae 00rpm rotating speed is to carry out centrifugal round as a ball step, can obtain the magnetic conductance microsphere that particle diameter is 0.2 ~ 0.6mm with the orifice plate of extruding in 0.3 ~ 1.0mm aperture.Then, the magnetic conductance microsphere water content obtained by extrusion spheronization processing procedure is higher, so need by fluidized drying, to make the magnetic conductance microsphere of experimental example 1-1 to 1-8.
The outward appearance of the raw material that preparation magnetic conductance microsphere is used and gained magnetic conductance microsphere arranges in Table 1.As shown in Table 1, substantially when magnetic conductance microsphere contains excipient (HPMC and MCC) of 50wt%, all granulating is carried out by extrusion spheronization method.
Table one: the outward appearance of the raw material that preparation magnetic conductance microsphere is used and gained magnetic conductance microsphere.
| Experimental example | SrO·6Fe 2O 3(g) | HPMC(g) | MCC(g) | Particle diameter (mm) | Outward appearance |
| 1-1 | 500 | 50 | 450 | 2.0 | Perfectly round outward appearance |
| 1-2 | 500 | 50 | 450 | 1.2 | Perfectly round outward appearance |
| 1-3 | 500 | 50 | 450 | 1.0 | Perfectly round outward appearance |
| 1-4 | 500 | 50 | 450 | 0.8 | Perfectly round outward appearance |
| 1-5 | 500 | 50 | 450 | 0.6 | Perfectly round outward appearance |
| 1-6 | 500 | 50 | 450 | 0.4 | Class circle outward appearance |
| 1-7 | 500 | 50 | 450 | 0.3 | Class circle outward appearance |
| 1-8 | 500 | 50 | 450 | 0.2 | Class circle outward appearance |
After material listed by table one is made magnetic conductance microsphere, observe the magnetic conductance microsphere before gained magnetization, all can adsorb by the magnetic sheet of 200 Gausses.Then measure the magnetic of magnetic conductance microsphere, obtain the maximum magnetic data before magnetizing.Then use magnetizer to magnetize the magnetic conductance microsphere of gained further, again measure the magnetic data after magnetization.In addition, also magnetic conductance microsphere is filled up No. 0 capsule, after microsphere can not be rocked in capsule, then magnetize and survey its magnetic.The data obtained is listed in table two.
Table two: the magnetic of magnetic conductance microsphere measured by before and after magnetization.
* external diameter 7.65mm, length 21.7mm, volume is 0.68mL.
As shown in Table 2, the size of magnetic conductance microsphere can affect the diversity of magnetic height.If the particle diameter of magnetic conductance microsphere is comparatively large, then the magnetic powder of single microsphere can have higher magnetic after magnetization.Compared with the magnetic (being about less than 3G) of magnetic powder, the magnetic of magnetic conductance microsphere can be increased to more than 3G.After magnetization, the magnetic of magnetic conductance microsphere can be increased to more than 40G, is on average about 20 times of the magnetic of magnetic powder.After capsule fills up magnetic conductance microsphere, then magnetize, its magnetic more can up to more than 140G.
Embodiment two: the solid magnetic conductance microsphere with shell
After experimental example 1-1 to 1-8 being wrapped shell below, obtain the solid magnetic conductance microsphere 200 with shell 210 as Fig. 2, wherein the material of shell is HPMC.Then magnetize, obtain the magnetic conductance microsphere with shell of experimental example 2-1 to 2-8.Measured data rows is in table three.Comparison sheet two is known with the data of table three, and the magnetic conductance microsphere 100 of Fig. 1, after having added shell 210, still maintains original magnetic size substantially, and namely the effect of magnetic influence of shell 210 pairs of magnetic conductance microspheres 100 is little.
Table three: have shell magnetic conductance microsphere magnetic after magnetization, wherein the weight of shell is 10% of core magnetic conductance microspheres weight.
| Experimental example | Record maximum magnetic (G) | Microsphere outward appearance |
| 2-1 | 105 | Perfectly round white |
| 2-2 | 99 | Perfectly round white |
| 2-3 | 103 | Perfectly round white |
| 2-4 | 92 | Perfectly round white |
| 2-5 | 75 | Perfectly round white |
| 2-6 | 53 | Class circle white |
| 2-7 | 52 | Class circle white |
| 2-8 | 49 | Class circle white |
Embodiment three: different magnetic powder material is on the impact of magnetic conductance microsphere magnetic
In the solid magnetic conductance microsphere of experimental example 3-1 to 3-15 below, change the material of magnetic powder, observe its impact on the magnetic of magnetic conductance microsphere.Prepare magnetic powder material used and have reduced iron (i.e. the ferrum of element state), ferrum rubidium boron alloy, ferric phrophosphate (for allowing edible chalybeate, purchased from Taiwan Yuan Hong company), Fe
2o
3with strontium ferrite (SrO6Fe
2o
3, can be used to prepare permanent magnet, purchased from Taiwan magnesium Lige Co., Ltd).
It is the chain saturated fatty acids (purchased from Taiwan Mei Lv company) with 46 carbon atoms at the material of this first substrate used.Water insoluble because of fusing point >60 DEG C of satisfied fatty acid for this reason, so the preparation method of magnetic conductance microsphere is hot fusion method and comminuting method, namely first heats satisfied fatty acid after it melts, then add dispersed-powder mixing, after its cooling, then pulverize molding.Finally, the microsphere sifting out required size scope is crossed with screen cloth.Acquired results is listed in table four.
Table four: the material of magnetic powder is on the impact of magnetic conductance microsphere magnetic
* reduced iron and ferric phrophosphate are all the edible chalybeate of Wei Fubu front, Taiwan tabular.
In table four, first can see and use SrO6Fe
2o
3for magnetic powder experimental example 3-13 to 3-15 after magnetization, secondly there is maximum magnetic, for using the experimental example 3-4 to 3-6 of ferrum rubidium boron alloy.As for using edible chalybeate ferric phrophosphate (experimental example 3-7 to 3-9) with reduced iron (experimental example 3-1 to 3-3) although the magnetic of magnetic conductance microsphere so not large, but its weak magnetic (being less than 300 Gausses) can make magnetic conductance microsphere on the contrary, and the dispersion under simulation digestive tract environment condition is better, and can have different application.Such as, the magnetic conductance microsphere of weak magnetic is easier to spread out in digestive tract, is on average attached on gastral fuzzy surface.
Secondly, use fusing point >60 DEG C and water-fast satisfied fatty acid as the host material of magnetic conductance microsphere at this, therefore can completely cut off magnetic powder, can not with the acid in the external world, alkali, oxidant and/or reducing agent effect, therefore can promote stability and the machinability of magnetic conductance microsphere.And satisfied fatty acid contributes to the position of fixing magnetic powder and arrangement orientation, therefore can form unidirectional magnetic pole after magnetization, increase magnetic, expand the range of application of magnetic conductance microsphere.
Embodiment four: water-soluble substances is on the impact of porous magnetic conductance microsphere outward appearance
Below in experimental example 4-1 to 4-6, extrusion spheronization method and water leaching is sequentially used to prepare porous magnetic conductance microsphere.Preparation method is after the homogeneous mixture first preparing ascorbic acid, magnetic powder and MCC, then adds the HPMC aqueous solution of 5wt%, Homogeneous phase mixing.Subsequently, use extrusion spheronization method allow the material just one-step formings such as the cellulose in raw material, form the substrate of magnetic conductance microsphere.
Then, allow magnetic conductance microsphere first dry in the shade 72 hours, reduce the water content of the magnetic conductance microsphere of about 30 ~ 50%.Then, allow comparatively dried magnetic conductance microsphere be dipped in 60% alcohol water blend of 500mL 6 hours, make dissolution of ascorbic acid in magnetic conductance microsphere in water, prepare more larger holes.After tentatively draining, allow magnetic conductance microsphere heating, drying 12 hours at 50 DEG C, make the last molding of magnetic conductance microsphere.Then, the loss in weight (weightless ratio) of magnetic conductance microsphere is measured, with the ascorbic acid stripping quantity estimating magnetic conductance microsphere, the pore volume increased and the outward appearance of observing magnetic conductance microsphere.
Table five: the content of water-soluble substances (ascorbic acid), on the impact of magnetic conductance microsphere outward appearance.
*MCC:HPMC＝95:5(w/w)。
Due in the process of preparation porous magnetic conductance microsphere, once allowed magnetic conductance microsphere be dipped in a period of time in water, the ascorbic acid therefore in magnetic conductance microsphere can be dissolved in the water, and prepares extra hole or increases original hole.Can be clear that from table five, when in raw material, ascorbic acid addition is more, the weight loss of magnetic conductance microsphere is more.But when water miscible ascorbic acid amount is too many (experimental example 4-1,80wt%), the outward appearance of porous magnetic conductance microsphere can cannot maintain integrity, and some micro-crineous material comes off.
Embodiment five: porous magnetic conductance microsphere
Magnetic conductance microsphere below prepared by experimental example 5-1 to 5-12 is porous magnetic conductance microsphere.The raw material that the magnetic conductance microsphere core of experimental example 5-1 to 5-12 is used is listed in table six, and preparation method is as described below.
First prepare lactic acid (lacticacid; LA, lactic acid is slightly soluble in water), after the homogeneous mixture of ascorbic acid, magnetic powder and MCC, then after the HPMC aqueous solution adding 5wt%, Homogeneous phase mixing.Subsequently, use extrusion spheronization method allow the material just one-step formings such as the cellulose in raw material, form the substrate of magnetic conductance microsphere.Then, allow magnetic conductance microsphere first dry in the shade 72 hours, reduce the water content of magnetic conductance microsphere.Come again, allow comparatively dried magnetic conductance microsphere be dipped in water 24 hours, allow the ascorbic acid in magnetic conductance microsphere be partially dissolved in water, prepare more and larger hole.Then, magnetic conductance microsphere is placed in high temperature furnace, heat 4 hours at 180 ~ 300 DEG C, to reduce contained humidity, and allow remaining lactic acid polymerizes overlap circlewise lactic acid (CyclicPolyLactate), increase caking property and the robustness of the first host material, make the last molding of magnetic conductance microsphere.
Table six: the raw material measured maximum magnetic rear with magnetization that preparation magnetic conductance microsphere is used
| Experimental example | Particle diameter (mm) | Strontium ferrite | HPMC(g) | MCC(g) | LA(g) | Ascorbic acid (g) | Magnetic (G) after magnetization |
| 5-1 | 2.0 | 500 | 50 | 450 | 0 | 0 | 135 |
| 5-2 | 2.0 | 500 | 50 | 100 | 350 | 0 | 118 |
| 5-3 | 2.0 | 500 | 50 | 0 | 350 | 100 | 110 |
| 5-4 | 2.0 | 500 | 50 | 100 | 0 | 350 | 122 |
| 5-5 | 1.2 | 500 | 50 | 450 | 0 | 0 | 129 |
| 5-6 | 1.2 | 500 | 50 | 100 | 350 | 0 | 122 |
| 5-7 | 1.2 | 500 | 50 | 0 | 350 | 100 | 102 |
| 5-8 | 1.2 | 500 | 50 | 100 | 0 | 350 | 113 |
| 5-9 | 1.0 | 500 | 50 | 450 | 0 | 0 | 131 |
| 5-10 | 1.0 | 500 | 50 | 100 | 350 | 0 | 110 |
| 5-11 | 1.0 | 500 | 50 | 0 | 350 | 100 | 101 |
| 5-12 | 1.0 | 500 | 50 | 100 | 0 | 350 | 108 |
From table six first, the magnetic of size on the porous magnetic conductance microsphere after magnetization has some to affect, and is approximately that its magnetic of particle diameter the greater is larger.The impact of the pore size of porous magnetic conductance microsphere and then.Addition according to water miscible ascorbic acid is how many, the pore size of known porous magnetic conductance microsphere.That is the addition of ascorbic acid is more, the aperture of porous magnetic conductance microsphere is larger.As shown in Table 6, the effect of magnetic influence of pore size to magnetic conductance microsphere is little.
Embodiment six: the magnetic conductance microsphere with shell
Below in experimental example 6-1 to 6-6, not containing any magnetic powder in the core texture of magnetic conductance microsphere, make into add magnetic powder in the shell of magnetic conductance microsphere.Architectural feature and the material therefor of experimental example 6-1 to 6-6 are listed in table seven.
Table seven: the shell as comparative example adds magnetic powder, can only obtain the magnetic conductance microsphere of weak magnetic, its magnetic is much smaller than embodiment above
* magnetic powder: HPMC=3:1 (w/w).
From table seven, compare with matched group (experimental example 6-1 with 6-4), the consumption more (namely gain in weight is more) of the Shell Materials of experimental group (experimental example 6-2v.6-3, experimental example 6-5v.6-6), measured magnetic is larger.But with in core texture, add the experimental example of magnetic powder by comparison above, magnetic or much little, the magnetic conductance microsphere of weak magnetic can only be obtained.
Embodiment seven: magnetic conductance complex microsphere
Experimental example 7-1 to 7-4 is the magnetic size of more single magnetic conductance microsphere and magnetic conductance complex microsphere (having the structure of Fig. 3 magnetic conductance complex microsphere 300) below, and acquired results is listed in table eight below.From table eight below, after magnetic conductance complex microsphere made by magnetic conductance microsphere, under particle diameter same case (experimental example 7-1 and 7-3), its magnetic can weaken.But, no matter be single porous magnetic conductance microsphere or magnetic conductance complex microsphere, after its particle diameter of increasing, its magnetic can be increased.
Table eight: the magnetic of magnetic conductance complex microsphere
* the solid magnetic conductance microsphere containing multiple particle diameter 0.3mm in magnetic conductance complex microsphere, the content of magnetic conductance microsphere is the 40wt% of magnetic conductance complex microsphere weight.
From disclosure above, due to the magnetic conductance microsphere of porous can be prepared, therefore after prepared by porous magnetic conductance microsphere, active substance that is liquid or suspended state can also be adsorbed in its hole; Or allow it enter digestive tract, utilize its hole to adsorb the toxin in digestive tract.Especially the pore size distribution range of porous magnetic conductance microsphere is quite wide, is about 0.1 ~ 20 μm, therefore optionally adsorbs vary in size and chemical substance that characteristic is different or biological substance by controlling its pore size.In addition, porous magnetic conductance microsphere can also be allowed to increase its stability and more different release characteristics by increase shell.And, because the particle diameter of magnetic conductance microsphere in this application can have wider change on demand, make it have wider range of application.
Although this utility model with embodiment openly as above; so itself and be not used to limit this utility model; any those skilled in the art; not departing from spirit and scope of the present utility model; when doing various variation and retouching, therefore protection domain of the present utility model is when being as the criterion depending on the claim person of defining.
Claims (10)
1. a therapeutic medical magnetic conductance microsphere, is characterized in that, described magnetic conductance microsphere comprises:
First substrate, described first substrate has multiple hole, and the material of described first substrate is upgraded fiber element or starch; And
Multiple magnetic powder, it intersperses among in described first substrate, and the material of described multiple magnetic powder is ferromagnetic material or paramagnetic material, has magnetic maybe can be induced magnetic to make described multiple magnetic powder.
2. therapeutic medical magnetic conductance microsphere as claimed in claim 1, is characterized in that, the aperture of described multiple hole is 0.1 ~ 20 μm.
3. therapeutic medical magnetic conductance microsphere as claimed in claim 1, is characterized in that, described upgraded fiber element is hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl-cellulose, microcrystalline Cellulose or its combination in any.
4. therapeutic medical magnetic conductance microsphere as claimed in claim 1, is characterized in that, the material of described multiple magnetic powder is the element state of ferrum, cobalt, nickel, rubidium or strontium, oxide, alloy, salt or its combination in any.
5. therapeutic medical magnetic conductance microsphere as claimed in claim 1, it is characterized in that, also comprise the first active substance, it intersperses among in described first substrate, described multiple hole or its combination, and described first active substance is for having bioactive chemical substance or biological substance.
6. therapeutic medical magnetic conductance microsphere as claimed in claim 1, is characterized in that, also comprise shell, and it is coated on the surface of described first substrate.
7. therapeutic medical magnetic conductance microsphere as claimed in claim 5, is characterized in that, the material of described shell is single candy, two candy, sugar alcohol, macromolecule or have fatty acid or its esters of 5 ~ 50 carbon.
8. a therapeutic medical magnetic conductance complex microsphere, is characterized in that, described therapeutic medical magnetic conductance complex microsphere comprises:
Second substrate; And
Magnetic conductance microsphere described in multiple any one of claim 1 ~ 7, it intersperses among in described second substrate.
9. therapeutic medical magnetic conductance complex microsphere as claimed in claim 8, is characterized in that, the material of described second substrate is micromolecular water-soluble substances, and described water-soluble substances is monosaccharide, aminoacid, organic acid or sugar alcohols compound.
10. therapeutic medical magnetic conductance complex microsphere as claimed in claim 8, is characterized in that, also comprise the second active substance and intersperse among in described second substrate, described second active substance is for having bioactive chemical substance or biological substance.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW104208531U TWM510759U (en) | 2015-05-29 | 2015-05-29 | Medical magnetic pellet |
| TW104208531 | 2015-05-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN204766639U true CN204766639U (en) | 2015-11-18 |
Family
ID=54506779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201520383009.5U Active CN204766639U (en) | 2015-05-29 | 2015-06-04 | Magnetic conductive microsphere for medical use |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN204766639U (en) |
| TW (1) | TWM510759U (en) |
-
2015
- 2015-05-29 TW TW104208531U patent/TWM510759U/en not_active IP Right Cessation
- 2015-06-04 CN CN201520383009.5U patent/CN204766639U/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWM510759U (en) | 2015-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Screening of enzyme inhibitors from traditional Chinese medicine by magnetic immobilized α-glucosidase coupled with capillary electrophoresis | |
| Dai et al. | 3D bioprinted glioma stem cells for brain tumor model and applications of drug susceptibility | |
| Finotelli et al. | Microcapsules of alginate/chitosan containing magnetic nanoparticles for controlled release of insulin | |
| Li et al. | Preparation of alginate/chitosan/carboxymethyl chitosan complex microcapsules and application in Lactobacillus casei ATCC 393 | |
| Dorożyński et al. | The macromolecular polymers for the preparation of hydrodynamically balanced systems—methods of evaluation | |
| Tavakol et al. | The effect of polymer and CaCl 2 concentrations on the sulfasalazine release from alginate-N, O-carboxymethyl chitosan beads | |
| Simpson et al. | NMR properties of alginate microbeads | |
| CN104414978B (en) | A kind of enteric-coated micro-pill containing esomeprazole magnesium | |
| Hamarat Sanlıer et al. | Development of gemcitabine-adsorbed magnetic gelatin nanoparticles for targeted drug delivery in lung cancer | |
| Bajpai et al. | Chemically treated hard gelatin capsules for colon‐targeted drug delivery: A novel approach | |
| JPH057376B2 (en) | ||
| WO2019088292A1 (en) | Hydrogel particle and method for producing same, cell or cell structure each enclosing hydrogel particle therein, method for evaluating activity of cell using hydrogel particle, and use of hydrogel particle as sustained release preparation | |
| Brax et al. | Gel formation mechanism and gel properties controlled by Ca2+ in chia seed mucilage and model substances | |
| Jiang et al. | Formulation and evaluation of gastroretentive floating drug delivery system of dipyridamole | |
| Sheng et al. | Encapsulation and characterisation of grape seed proanthocyanidin extract using sodium alginate and different cellulose derivatives | |
| CN204766639U (en) | Magnetic conductive microsphere for medical use | |
| Zhu et al. | Fluorinated ionic liquid based multicolor 19F MRI nanoprobes for in vivo sensing of multiple biological targets | |
| Uddin et al. | Enhanced bioavailability of orally administered antisense oligonucleotide to nuclear factor kappa B mRNA after microencapsulation with albumin | |
| CN106267216A (en) | Magnetic conductive microsphere for medical use | |
| CN105343031B (en) | A kind of ivermectin solid lipid nano granule and preparation method thereof | |
| CN108310046A (en) | A kind of targeted micro-capsule of sophora alapecuroides and preparation method thereof | |
| CN101606950A (en) | A kind of pediatric paracetamol,atificial cowbezoar and chlorphenamine maleate granule and method of quality control | |
| Dong et al. | Preparation and properties of a pH sensitive carrier based on three kinds of polymer blend to control the release of 5-amino salicylic acid | |
| CN102727445A (en) | Sophocarpidine pH/ magnetic dual-sensitive hydrogel globule and preparation method thereof | |
| CN114317442A (en) | Culture medium for establishing mammary gland organoid or/and breast cancer organoid, method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210908 Address after: 14-22 Quanzhou Road, Houli District, Taichung, Taiwan, China Patentee after: Yongpeng Shengke Co.,Ltd. Patentee after: Hansford Biotechnology Co.,Ltd. Address before: 1 / F, no.6, Lane 40, Xiaoqian street, Banqiao District, Xinbei, Taiwan, China Patentee before: bio-Peptide Enhancer Tech Inc.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220523 Address after: 14-22 Quanzhou Road, Houli District, Taichung, Taiwan, China Patentee after: Yongpeng Shengke Co.,Ltd. Address before: 14-22 Quanzhou Road, Houli District, Taichung, Taiwan, China Patentee before: Yongpeng Shengke Co.,Ltd. Patentee before: Hansford Biotechnology Co., Ltd |